Formulation and evaluation of bioadhesive buccal drug delivery of tizanidine hydrochloride tablets

AAPS PharmSciTech

Volumn 10, Issue 2, 2009, Pages 530-539

  Shanker, Gazzi ^a   Kumar, Chegonda K ^a   Gonugunta, Chandra Sekhara Rao ^a   Kumar, B Vijaya ^a   Veerareddy, Prabhakar Reddy ^a  

^a ST PETER'S INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Bioadhesive buccal tablets; In vitro evaluation; In vivo mucoadhesive behavior; Permeation enhancers; Stability studies in natural saliva; Tizanidine hydrochloride

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; CARBOXYMETHYLCELLULOSE; DEOXYCHOLATE SODIUM; HYDROXYPROPYLMETHYLCELLULOSE; TIZANIDINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DRUG DERIVATIVE;

ADHESION; ADULT; ANIMAL TISSUE; ARTICLE; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NONHUMAN; NORMAL HUMAN; PH; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; SUSTAINED RELEASE FORMULATION; SWINE; TABLET COMPRESSION; TABLET DISINTEGRATION TIME; TABLET FORMULATION; TABLET HARDNESS; TABLET THICKNESS; CHEEK; CHEMISTRY; DELAYED RELEASE FORMULATION; METABOLISM; MOUTH MUCOSA; ORAL DRUG ADMINISTRATION; SOLUBILITY; TABLET; THEORETICAL MODEL;

ADHESIVENESS; ADMINISTRATION, ORAL; ADRENERGIC ALPHA-AGONISTS; ADULT; CHEEK; CHEMISTRY, PHARMACEUTICAL; CLONIDINE; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; HUMANS; MODELS, THEORETICAL; MOUTH MUCOSA; SOLUBILITY; TABLETS;

EID: 67549107135     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9241-2     Document Type: Article

References (49)

1. Squier CA, Wertz PW. Structure and function of the oral mucosa and implications for drug delivery. In: Rathbone MJ, editor. Oral mucosal drug delivery. New York: Marcel Dekker; 1996. p. 1-2.
2. Gibaldi M. The number of drugs administered buccally is increasing. Clin Pharmacol 1985;3:49-56.
3. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 1992;81:1-10.
4. Davis SS, Daly PB, Kennerley JW, Frier M, Hardy JG, Wilson CG. Design and evaluation of sustained release formulations for oral and buccal administration. In: Bussmann WD, Dries RR, Wagner W, editors. Controlled release nitroglycerin in buccal and oral form. Basle: Karger; 1982. p. 17-25.
5. Schor JM, Davis SS, Nigalaye A, Bolton S. Susadrin transmucosal tablets. Drug Dev Ind Pharm 1983;9:1359-77.
6. Ishida M, Nambu N, Nagai T. Mucosal dosage form of lidocaine for toothache using hydroxypropyl cellulose. Chem Pharm Bull 1982;30:980-4.
7. Bremecker KD, Strempel H, Klein G. Novel concept for a mucosal adhesive ointment. J Pharm Sci 1984;73:548-52.
8. Anders R, Merkle HP. Evaluation of laminated mucoadhesive patches for buccal drug delivery. Int J Pharm 1989;49:231-40.
9. Gandhi RB, Robinson JR. Bioadhesion in drug delivery. Ind J Pharm Sci 1988;50:145-52.
10. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: A review. J Pharm Pharmaceut Sci 1998;1(1):15-30.
11. Nagai T, Machida Y. Advances in drug delivery: Mucosal adhesive dosage forms. Pharm Int 1985;6:196-200.
12. Chattarajee SC, Walker RB. Penetration enhancer classification. In: Smith EW, Maibach HI, editors. Percutaneous penetration enhancement. Boca Raton: CRC; 1995. p. 1-4.
13. Aungst BJ, Rogers NJ. Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery. Int J Pharm 1989;53:227-35.
14. Lee VHL, Yamamoto A, Kompella UB. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit Rev Ther Drug Carrier Syst 1991;8:91-192.
15. Pitha J, Harman SM, Michel ME. Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones. J Pharm Sci 1986;75:165-7.
16. Burnside BA, Keith AD, Snipes W. Microporous hollow fibers as a peptide delivery system via the buccal cavity. Proc Int Symp Control Release Bioact Mater 1989;16:93-4.
17. Zhang J, Niu S, Ebert C, Stanley TH. An in - vivo dog model for studying recovering kinetics of the buccal mucosa permeation barrier after exposure to permeation enhancers: Apparent evidence of effective enhancement without tissue damage. Int J Pharm 1994;101:15-22.
18. Steward A, Bayley DL, Howes C. The effect of enhancers on the buccal absorption of hybrid (BDBB) alpha interferon. Int J Pharm 1994;104:145-9.
19. Ebert CD, Heiber SJ, Dave SC, Kim SW, Mix D. Mucosal delivery of macromolecules. J Control Release 1994;28:37-44.
20. Hoogstraate AJ, Wertz PW, Squier CA, Bos Van Geest A, Abraham W, Garrison MD, Verhoef JC, Junginger HE, Bodde' HE. Effects of the penetration enhancer glycodeoxycholate on the lipid integrity in porcine buccal epithelium in vitro. Eur J Pharm Sci 1997;5:189-98.
21. Nance PW, Bugaresti J, Shellenberger K, the North American Tizanidine Study Group. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology 1994;44:S44-51.
22. United Kingdom Tizanidine Trial Group. A double blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994;44:S70-8.
23. Wagstaff AJ, Bryson HM. Tizanidine: A review of its pharmacology, clinical efficacy, and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;53:435-52.
24. Acorda Therapeutics, Inc. Zanaflex® (tizanidine hydrochloride) tablets and capsules prescribing information. Hawthorne: Acorda Therapeutics; 2006.
25. Moffat AC. Clark's isolation and identification of drugs. London: Pharmaceutical Press; 2006. p. 691.
26. Tanaka M, Yanagibashi N, Fukuda H, Nagai T. Absorption of salicylic acid through the oral mucous membrane of hamster cheek pouch. Chem Pharm Bull (Tokyo) 1980;28:1056-61.
27. Zuber M, Chemtob C, Chanmeil J. Sci Tech Pharm 1979;8:1.
28. Bandyopadhyay AK, Metia PK. In vitro evaluation of novel mucoadhesive buccal tablets of oxytocin prepared with diospyros peregrina fruits mucilage. Yakugaku Zasshi 2008;128:603-9.
29. Mumtaz AM, Ch'ng HS. Design of a dissolution apparatus suitable for in situ release study of triamcinolone acetonide from bioadhesive buccal tablets. Int J Pharm 1995;121:129-39.
30. Remuñán-López C, Portero A, Vila-Jato JL, Alonso MJ. Design and evaluation of chitosan/ethyl cellulose mucoadhesive bilayered devices for buccal drug delivery. J Control Release 1998;55:143-52.
31. Sujatha K, Chitra K, Hettiarachchi DS, Vinay Krishna M, Vasantha J. Spectrophotometric determination of tizanidine hydrochloride. Indian J Pharm Sci 2003;65:519-20.
32. United States Pharmacopoeia, National Formulary. By authority of united state Pharmacopoeia Convention, Inc., Meeting at Washington, 2004, p. 2302.
33. Gupta A, Garg S, Khar RK. Measurement of bioadhesive strength of mucoadhesive buccal tablets: Design of an in vitro assembly. Indian Drugs 1993;30:152-5.
34. Nakamura F, Ohta R, Machida Y, Nagai T. In vitro and in vivo nasal mucoadhesion of water soluble polymers. Int J Pharm 1996;134:173-81.
35. Tirosh B, Baluom M, Nassar T, Friedman M, Rubinstein A. The effect of Eudragit RL-100 on the mechanical and mucoadhesion properties of polycarbophil dosage forms. J Control Release 1997;45:57-64.
36. Ritthidej GC, Phaechamud T, Koizumi T. Moist heat treatment on physicochemical change of chitosan salt films. Int J Pharm 2002;232:11-22.
37. Bottenberg P, Cleymaet R, Muynek CD, Remon JP, Coomans D, Slop D. Development and testing of bioadhesive, fluoride-containing slow-release tablets for oral use. J Pharm Pharmacol 1991;43:457-64.
38. Be'cirevi'c-La'can M, Jug M. Influence of hydroxypropyl-beta-cyclodextrin complexation on piroxicam release from buccoadhesive tablets. Eur J Pharm Sci 2004;21:251-60.
39. Kashappa Goud Desai H, Pramod Kumar TM. Preparation and evaluation of a novel buccal adhesive system. AAPS PharmSciTech 2004;5:35.
40. Periolia L, Ambrogia V, Angelicia F, Riccia M, Giovagnolia S, Capuccellab M, Rossia C. Development of mucoadhesive patches for buccal administration of ibuprofen. J Control Release 2004;99:73-82.
41. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13(2):123-33.
42. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985;60:110-1.
43. Longer MA, Robinson JR. Fundamental aspects of bioadhesion. Pharm Int 1986;7:114-7.
44. Park H, Robinson JR. Mechanisms of mucoadhesion of poly (acrylic acid) hydrogels. Pharm Res 1987;4:457-64.
45. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992;78:43-8.
46. Peppas NA, Bury PA. Surface interfacial and molecular aspects of polymer bioadhesion on soft tissues. J Control Release 1985;2:257-75.
47. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech 2005;6:E329-57.
48. Gandhi R, Robinson J. Mechanisms of penetration enhancement for transbuccal delivery of salicylic acid. Int J Pharm 1992;85:129-40.
49. Choi HG, Kim CK. Development of omeprazole buccal adhesive tablets with stability enhancement in human saliva. J Control Release 2000;68:397-404.